EP3456339
Nýstárleg ónæmismeðferð við nokkrum gerðum æxla, til dæmis lungnakrabba, þar með talin lungnakrabbamein önnur en smáfrumukrabbamein (NSCLC)
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
4.8.2014EP published:
20.10.2021EP application number:
18201334.2
EP translation filed:
30.11.2021Grant published:
15.1.2022EPO information:
European Patent Register
Max expiry date:
3.8.2034Expiry date:
3.8.2024
Title:
NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER INCLUDING NSCLC
Timeline
Today
4.8.2014EP application
20.10.2021EP Publication
30.11.2021Translation submitted
15.1.2022Registration published
3.8.2024Expires
Owner
Name:
immatics biotechnologies GmbHAddress:
Paul-Ehrlich-Strasse 15, 72076 Tübingen, DE
Inventor
Name:
FRITSCHE, JensAddress:
72144 Dusslingen, DE
Name:
SINGH, HarpreetAddress:
80804 München, DE
Name:
SONG, ColetteAddress:
73760 Ostfildern, DE
Name:
WALTER, SteffenAddress:
Houston, TX Texas 77005, US
Name:
WEINSCHENK, ToniAddress:
73773 Aichwald, DE
Agent
Name:
KIPA ABAddress:
Pósthólf 1065, Drottninggatan 11, SE
Priority
Number:
201313987Date:
5.8.2013Country:
GB
Number:
201361862213 PDate:
5.8.2013Country:
US
Number:
201403297Date:
25.2.2014Country:
GB
Classification
Categories:
A61K 38/17, A61K 39/00, C07K 7/06, C12N 5/0783
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 17.8.2022
Expires: 3.8.2023
Payer: Patice ehf.
Number: 10
Paid: 28.8.2023
Expires: 3.8.2024
Payer: Árnason Faktor ehf.